Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOLANTHE: Olaparib + Bevacizumab in HRD+ Ovarian Cancer
NCT06121401Phase 4Active, not recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 4 trial of olaparib in epithelial ovarian cancer (EOC), sponsored by Mario Negri Institute for Pharmacological Research. Started Sep 2023; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT06121401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121401.